Guildford, United Kingdom

ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.

Investment Perspective

ANGLE’s business update outlines the progress made in 2022, including the FDA clearance of Parsortix to harvest cancer cells from patient blood for subsequent analysis in mBC (metastatic breast cancer) and the highly positive ovarian cancer data. Management’s strategy remains focused on making Parsortix broadly available to industry and patients. However, market conditions are notably challenging and have prolonged partnering discussions and delayed commercial uptake. Headwinds include broad pricing and cost pressures impacting all industry participants, and funding constraints, especially affecting smaller healthcare companies. Regardless of these external factors, ANGLE remains confident in its commercial strategy to make Parsortix broadly available to industry and patients, which is focused on three key areas: pharma services, corporate partnerships, and a product-led business (either directly or via distributors).

Market information

SymbolPrimary exchanges


FY22: a year of two very distinct halves
Lighthouse | 05 Jan 2023
Post-FDA approval commercial momentum is building
Lighthouse | 29 Sep 2022
£20m raise funds commercialisation through to mid-2024
Lighthouse | 15 Jul 2022

Recent News

Business update
05 Jan 2023
NED appointment
05 Jan 2023
Two Parsortix posters presented at SABCS
12 Dec 2022
Multiple downstream analysis techniques for CTCs
02 Nov 2022